TNXP Tonix Pharmaceuticals produces the Monkeypox Vaccine !

NASDAQ:TNXP   Tonix Pharmaceuticals Holding Corp.
Tonix is a producer of the TNX-801 vaccine, effective against Smallpox and Monkeypox.

But that`s not all!

They have a strong balance sheet, Cash and Cash Equivalents Totaled Approximately $140 Million VS its mk cap of only $44.03Mil.

Seth Lederman, M.D., Chief Executive Officer of Tonix: “Tonix is making meaningful strides developing our rich portfolio of high impact product candidates,”
“By the end of this year, we expect to have five central nervous system (CNS) programs in the clinic, led by our most advanced program, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, which is in mid-Phase 3 development. Enrollment has begun for TNX-102 SL in a registration-enabling-Phase 3 clinical trial. TNX-102 SL trials in Long COVID and PTSD are also expected to initiate enrollment in the second quarter of 2022.”

TNX-2900 received Orphan-Drug designation by the FDA for the treatment of PWS in March 2022.

On this strong pipeline, on 4/18/2022 Noble Financial Initiated Coverage on TNXP with an Outperform rating and a price target of $19.20, while Alliance Global Partners has a price target of $64.

I expect TNXP Tonix Pharmaceuticals to be at least $10 per share.

Looking forward to read your opinion about it.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.